Jennerex, Inc. – Trademark Portfolio

Entity Type: 03

Jennerex, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include TARGETING, ATTACKING AND ERADICATING CANCERS. The owner is based in San Francisco, CA.

450 Sansome Street, 16th Floor

San Francisco, CA 94111

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Jennerex, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Jennerex, Inc. have?

Jennerex, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 cancelled.

What trademark classes does Jennerex, Inc. file in?

Jennerex, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Jennerex, Inc.'s most well-known trademarks?

Jennerex, Inc.'s registered trademark portfolio includes well-known marks such as TARGETING, ATTACKING AND ERADICATING CANCERS. These are among 1 currently registered trademark in the portfolio.

What is Jennerex, Inc.'s trademark registration success rate?

Jennerex, Inc. has a 17% trademark registration rate, with 1 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.